FLORHAM PARK, New Jersey, November 29, 2018 /PRNewswire/ — The pharmaceutical multinational Exeltis, with a strong position in Women's Health, has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda (4mg…Original Article
FDA Accepts Filing of New Estrogen-free Oral Contraceptive Slinda (drospirenone) Developed by Exeltis
